Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D475/00—Heterocyclic compounds containing pteridine ring systems
  • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
  • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
  • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
  • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
  • C07D473/32—Nitrogen atom
  • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D475/00—Heterocyclic compounds containing pteridine ring systems
  • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Definitions

• This invention concerns heterocyclic compounds and, more particularly, certain furyl-substituted purines, oxazolopyrimidines and pteridines which have useful pharmacological properties (and in particular antagonise the actions of adenosine such as vasodilation).
• the invention also includes pharmaceutical compositions containing the heterocyclic compounds for use in treating certain diseases and disorders affecting mammalian cardiac, peripheral and/or cerebral vascular systems. Also included are processes for the manufacture and formulation of the heterocyclic compounds.
• the compound theophylline (1,3-dimethylxanthine) has been used clinically (usually as its ethylene diamine salt, which is also known as aminophylline) as a respiratory stimulant, a centrally acting stimulant, a bronchodilator, a cardiac stimulant and as a diuretic.
• This diversity of clinical uses is an indication of the range of pharmacological actions which have been attributed to theophylline. These include phosphodiesterase inhibition, adenosine receptor antagonism, mobilisation of intracellular calcium and the release of catecholamines.
• the "vascular steal” phenomenon can occur when the major artery supplying a particular vascular bed is partially or totally occluded resulting in ischaemia.
• the compromised vascular bed dilates and blood flow is maintained by either an increase in flow across the narrowed vessel or by an increase in flow through the collateral vessels.
• increased metabolic activity in adjacent vascular beds results in release of mediators such as adenosine, causing them to dilate, resulting in the limited blood flow to the compromised vascular bed being "stolen” by these adjacent areas.
• the loss of blood from compromised to normally perfused vascular beds by the phenomenon of "vascular steal” further diminishes the blood flow in the compromised vascular bed.
• the diversity of pharmacological properties possessed by theophylline make it difficult to use in the regular treatment or prevention of occlusive diseases and conditions of the vasculature.
• its associated action as a phosphodiesterase inhibitor results in cardiac stimulation which is deleterious for patients with myocardial ischaemia.
• the relatively low potency of theophylline means that dose-levels which are therapeutically useful are close to those which can cause serious central side-effects.
• the formula I compounds may exist in and be isolated in one or more different enantiomeric or racemic forms (or a mixture thereof). It is to be understood that the invention includes any of such forms which possesses the property of antagonising the actions of adenosine, it being well known how to prepare individual enantiomeric forms, for example, by synthesis from appropriate chiral starting materials or by resolution of a racemic form. Similarly, the adenosine antagonist properties of a particular form may be readily evaluated, for example by use of one or more of the standard in vitro or in vivo screening tests detailed hereinbelow.
• R 1 when it is (1-6C)alkyl is, for example, methyl, ethyl, propyl or butyl, and when it is (1-4C)alkanoyl is, for example, formyl, acetyl or propionyl.
• R 1 is hydrogen
• a particular value for R 3 when it is (3-12C)cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or norbornyl.
• R 3 when it is (3-6C)alkenyl is allyl.
• R 3 when it is phenyl(3-6C)alkenyl is 3-phenyl-2-trans-propenyl.
• R 3 when it is 5- or 6-membered heteroaryl include, for example, pyridyl, isoxazolyl or thiadiazolyl.
• R 3 is optionally substituted (1-6C)alkyl are, for example, methyl, ethyl, isopropyl, propyl, butyl, sec-butyl and n-pentyl.
• R 3 is optionally substituted alkyl (such as methyl or ethyl)
• R 3 is optionally substituted alkyl (such as methyl or ethyl)
• R 3 represents the group R 4 (CO)mXa(CO)M
• n is O when Xa is -NRb, and Rb, together with R 4 and the adjacent nitrogen atom form a 4 to 6-membered saturated heterocyclic ring.
• optional substituents on an optionally substituted phenyl include, for example:
• One of the substituents on a substituted phenyl group is preferably in the para position.
• a particular value for Ra when it is (1-6C)alkyl is, for example, methyl or ethyl.
• X include, for example, oxy, thio, NH, methylimino or, together with R 3 , morpholino, thiomorpholino, pyrrolidino, piperidino or azetidino.
• R 8 include, for example hydrogen and methyl.
• a group of compounds of particular interest consists of those compounds of formula I wherein:
• R 2 is a 4-chlorobenzyl, 2-phenylethyl, 2-phenylethylamino, 2-(4-hydroxyphenyl)ethylamino, 2-(4-methylphenyl)ethylamino, 2-(4-methoxyphenyl)ethylamino or 2-(3,4-dimethoxyphenyl)ethylamino are especially preferred.
• Particular pharmaceutically acceptable salts include, for example, salts with acids affording physiologically acceptable anions, for example, salts with strong acids, such as hydrochloric, hydrobromic, sulphuric, phosphoric, methanesulphonic and trifluoracetic acids.
• suitable salts include, for example, salts with organic acids affording a physiologically acceptable anion such as salts with oxalic, citric or maleic acid.
• Certain compounds of formula I for example those in which R 2 comprises a phenol group, may form base salts with bases affording physiologically acceptable cations, such as alkali metal and alkaline earth metal salts.
• the compounds of formula I may be manufactured using procedures analogous to those well known in the arts of heterocyclic and organic chemistry for the production of structurally analogous compounds. Such procedures are included as a further feature of the invention and include the following preferred procedures for the manufacture of a compound of the formula I in which R l , R 2 , X, A and Q have any of the meanings defined above:
• the process is conveniently effected at a temperature in the range of, for example, from 0 to 120°C.
• Suitable solvents for the process include alcohols such as ethanol or isopropanol, and ethers such as tetrahydrofuran.
• R 1 is hydrogen, it is particularly convenient to employ a solution of ammonia in an alcohol, such as ethanol or isopropanol, at ambient temperature.
• the reaction may conveniently be performed in the presence of a solvent such as an alcohol (for example ethanol), a tertiary amine (for example pyridine) or a halogenated hydrocarbon, (for example chloroform).
• a solvent such as an alcohol (for example ethanol), a tertiary amine (for example pyridine) or a halogenated hydrocarbon, (for example chloroform).
• a base such as a tertiary amine (for example dimethylaminopyridine or pyridine).
• the temperature at which the reaction is performed is conveniently in the range of from 25 to 150 °C, for example from 60 to 100 °C.
• the solvent conveniently comprises ethanol and water.
• reaction is preferably performed in the presence of an acid, for example a mineral acid such as sulphuric acid or hydrochloric acid.
• an acid for example a mineral acid such as sulphuric acid or hydrochloric acid.
• the compound of formula V may conveniently be cyclised by treatment with a dehydrating agent, for example phosphorus pentoxide or phosphorus oxychloride.
• a dehydrating agent for example phosphorus pentoxide or phosphorus oxychloride.
• the cyclisation may be performed in the presence or absence of a solvent, conveniently at a temperature in the range of from 0 to 150 °C, for example from 50 to 120 °C.
• the alkylating agent may be a conventional alkylating agent such as a (1-4C)alkyl halide or di(1-4C)alkyl sulphate.
• the reaction is conveniently performed in the presence of a base, such as an alkali metal carbonate or hydroxide (for example, potassium carbonate).
• a base such as an alkali metal carbonate or hydroxide (for example, potassium carbonate).
• Suitable solvents for the reaction include amides (for example dimethylformamide), ethers (for example tetrahydrofuran) and alcohols (for example ethanol).
• the temperature at which the reaction is performed is conveniently in the range of from 0 to 100 °C.
• the reaction may conveniently be performed in the presence of a solvent such as an amide (for example dimethylformamide), and at at temperature in the range of from 25 to 150 °C, for example from 60 to 120 °C.
• a strong base for example an alkali metal alkoxide such as potassium t-butoxide.
• the reaction may conveniently be performed in the presence of a solvent such as a nitrile (for example acetonitrile), an ether (for example t-butyl methyl ether, tetrahydrofuran or 1,2-dimethoxyethane) or an amide (for example dimethylformamide), and at a temperature in the range of from 10 to 120 °C, for example from 30 to 80 °C.
• a solvent such as a nitrile (for example acetonitrile), an ether (for example t-butyl methyl ether, tetrahydrofuran or 1,2-dimethoxyethane) or an amide (for example dimethylformamide), and at a temperature in the range of from 10 to 120 °C, for example from 30 to 80 °C.
• the reaction is preferably performed under basic conditions, which may be provided by the inherent basicity of the compound of formula R3XH or a salt thereof, or by a base such as a tertiary
• those compounds of formula I in which R 3 contains an acyloxy group may be prepared by acylating the corresponding compounds of formula I in which R 3 comprises a hydroxy group, as for example where R 3 is hydroxyphenyl or hydroxyphenyl(1-4C)alkyl.
• the acylation may be conducted by reaction with any conventional acylating agent, for example a (1-4C)alkanoyl halide or (1-4C)alkanoic acid anhydride.
• a pharmaceutically acceptable salt it may be obtained, for example, by reacting a compound of formula with the appropriate acid or base affording a physiologically acceptable ion or another conventional procedure.
• the starting materials used in the processes according to the invention are either known or may be prepared using techniques well known in the arts of heterocyclic and organic chemistry.
• the compounds of formula II in which Z 1 represents a halogen atom may be prepared from a compound of formula IX in which R 12 represents a hydrogen atom or an alkoxy group (for example ethyl) and R 13 and R 14 are as defined for R 10 and R 11 above according to the method of process (c) above, but using as the dehydrating agent a reagent which is also a halogenating agent, for example phosphorus oxychloride.
• the reaction may be performed in the presence or absence of a solvent (such as dimethylformamide) at a temperature in the range of from 0 to 150 °C.
• the compounds offormula III may be prepared by reacting a compound of formula Xwith a reducing agent, for example sodium dithionite, conveniently in the presence of a solvent such as aqueous ethanol.
• a reducing agent for example sodium dithionite
• R 2 represents a group capable of functioning as a leaving group, for example a (1-4C)al- kylthio group (such as methylthio)
• R 3 XH where X is, for example, NH.
• the reaction may conveniently be performed in the presence of a solvent such as water at a temperature in the range of from 40 to 120 °C.
• R 9 is a leaving group such as a halogen atom (for example a chlorine atom).
• the reaction is conveniently performed in the presence of a solvent such as chloroform and in the presence of a base such as triethylamine.
• the temperature at which the reaction is performed is conveniently in the range of from 0 to 100 °C.
• R 2 represents a group capable of functioning as a leaving group, for example a (1-4C)alkylthio group (such as methylthio)
• R 3 XH where X is, for example, NH.
• the reaction may conveniently be performed in the presence of a solvent such as water at a temperature in the range of from 40 to 120 °C.
• the compounds of formula VI may be prepared by conventional methods.
• the compounds of formula VIII may be prepared by methods analagous to those which may be used to prepare compounds of formula I.
• Compounds of formula VIII in which Z 2 represents a (1-4C)alkylsulphonyl group may be prepared by reacting a compound of formula I in which R 2 represents a (1-4C)alkylthio group with an oxidising agent such as peracetic, perbenzoic or chloroperbenzoic acid.
• the oxidation may conveniently be performed in the presence of a solvent such as dichloromethane at a temperature in the range of from 0 to 40 °C.
• the compounds of formula IX may be prepared by reacting a compound of formula VII with a compound of formula (R 15 OOC)CHNHCOQ in which R 15 is a (1-4C)alkyl group such as ethyl, or with a compound of formula XII (preparable by reacting a compound of formula (R 15 OOC)CHNHCOQ with a dehydrating agent such as phosphorus pentoxide supported on silicon dioxide).
• a dehydrating agent such as phosphorus pentoxide supported on silicon dioxide.
• the reaction is conveniently performed in the presence of a base, such as sodium methoxide or potassium carbonate, and a solvent such as dimethylformamide.
• the temperature at which the reaction is performed is conveniently in the range of from 25 to 120 °C.
• the compounds of formula X may be prepared by reacting a compound of formula XI with an alkali metal nitrite in the presence of an acid such as hydrochloric acid. The reaction is conveniently performed in the presence of a solvent such as aqueous ethanol at a temperature in the range of from 25 to 100 °C.
• the compounds of formula I possess the property of antagonising one or more of the physiological actions of adenosine and are valuable in the treatment of diseases and medical conditions affecting the mammalian cardiac, peripheral and/or cerebral vascular systems, such as ischaemic heart disease, peripheral vascular disease (claudication) and cerebral ischaemia.
• the compounds may also be useful in the treatment of migraine.
• This test involves the ability of a test adenosine antagonist to displace the known adenosine mimetic agent [ 3 H]-N-ethylcarboxamidoadenosine (NECA) from binding sites on membrane preparations derived from the rat phaeochromocytoma cell line PC 12 (available from the Beatson Institute, Glasgow).
• NECA adenosine mimetic agent
• PC 12 available from the Beatson Institute, Glasgow
• the membrane preparation is obtained as follows:
• Binding studies are carried out in microtitre plates, the assay mixtures being buffered in 50 mM tris-HCI, pH 7.4 at room temperature.
• the test compound is dissolved in dimethyl sulphoxide (DMSO) and then diluted with assay buffer to give the test solutions.
• DMSO dimethyl sulphoxide
• the final concentration of DMSO is not allowed to exceed 1% by volume, at which level it does not affect radioligand binding to the membrane receptor.
• Incubations are performed at 30°C for 90 minutes in a total volume of 150 ⁇ l comprising the test solution or buffer (50 ⁇ l), tritiated NECA (50 ⁇ l) and membrane suspension (50 ⁇ l).
• the samples are rapidly filtered over glass- fibre mats and the filter mats are washed to remove non-receptor-bound radioligand.
• Receptor-bound radioligand entrapped on the filter mats is then determined by liquid scintillation counting. Filtration and washing are carried out using a conventional vacuum filtration cell harvester.
• the specific binding (defined as the difference between the total binding and the non-specific binding) in the presence of the particular test compound is determined and compared with the control value. Results are conveniently expressed as the negative logarithm of the concentration required to cause a 50% displacement of control specific binding (pIC 50 ).
• compounds of the formula I showing antagonist activity in this assay typically show a pIC 50 in the above test (a) of 6 or more.
• the compound of Example 1 herein showed a 78% displacement of control binding at a concentration of 10- 5 M and 59% displacement at 1 0-7M, indicating a pIC 50 of greater than 7.
• the known compound 1,3-dimethylxanthine typically shows a pIC 50 of about 5.
• This test has also been described by Collis et al.(British J. Pharmacology, 1989, 97, 1274-1278) and involves the ability of a test compound to antagonise the bradycardic effect of the adenosine mimetic, 2-chloroadenosine, in a beating guinea-pig atrial preparation, an effect mediated via the adenosine receptor known as A 1 .
• the atrial pair preparation may be obtained as follows:-Atrial pairs are obtained from guinea-pigs (Dunkin Hartley strain, 250-400g males) and mounted in organ baths containing oxygenated Krebs buffer solution (95% O2; 5% CO2) at 37°C. The spontaneously beating atria are then placed under a resting tension of 1 g and allowed to equilibrate for 50 minutes with continuous overflow. Overflow is then stopped and adenosine deaminase (1 Unit ⁇ ml) added to prevent the accumulation of endogenously produced adenosine.
• a cumulative dose response curve to the adenosine mimetic, 2-chloroadenosine (10- 8 M to 10-4M) is administered to produce a maximal slowing of atrial rate.
• adenosine deaminase is readministered to the bath which is allowed to equilibrate for 15 minutes.
• a 10-sfvt solution of the test compound in DMSO is then added to the bath which is left to incubate for 30 minutes. Any effect on the beating rate due to the test compound is noted before the dose response curve to 2-chloroadenosine is repeated.
• Compounds which are adenosine antagonists attenuate the 2-chloroadenosine response.
• Test compounds are assessed by comparing dose response curves to 2-chloroadenosine alone with those obtained in the presence of the compound.
• Competitive adenosine antagonists produce a parallel shift in the 2-chloroadenosine dose response curve.
• the dose ratio (DR) is calculated from the ratio of the concentration of 2-chloroadenosine to produce a 50% reduction in atrial rate (ED 50 ) in the presence of the test compound divided by the ED 50 concentration of 2-chloroadenosine in the absence of the test compound for each atrial pair.
• the pA2 which is an estimate of the concentration of antagonist required to give a dose ratio of 2
• the known compound, 1,3-dimethylxanthine typically shows a pA2 of about 5.
• This test assesses the ability of a test compound to antagonise the fall in diastolic blood pressure produced by administration of the adenosine mimetic, 2-chloroadenosine.
• mice Male cats (2 - 3 kg) are anaesthetised with sodium pentobarbitone (45 mg/kg, ip).
• the following blood vessels are catheterised: right jugular vein (for infusion of the anaesthetic at approximately 7 mg/kg per hour as a 3 mg/ml solution in isotonic saline), the left jugular vein (for administration of test agents) and the right common carotid artery (for monitoring blood pressure and pulse rate).
• the blood gas status and pH are determined, and are maintained within physiological limits, before administration of 2-chloroadenosine.
• a control dose response curve (DRC) to 2-chloroadenosine (0.3 to 30 pg/kg) against the fall in diastolic blood pressure is determined.
• DRC control dose response curve
• a solution of the test compound in a mixture of 50% v/v polyethylene glycol (PEG) 400 and 0.1 M sodium hydroxide is then administered i.v. and after 15 minutes the DRC to 2-chloroadenosine is determined. This procedure is repeated twice with blood gases and pH being monitored and maintained within physiological limits between each DRC.
• the concentration of2-chloroadenosine required to cause a 30 mm Hg fall in diastolic blood pressure is then calculated for each dose of test compound and a Schild plot constructed for those which produce a dose ratio (DR) of >2. From this plot a K B value is determined.
• Test compounds which are active in this test will possess a K B value of 1 mg/kg (or much less).
• Test (c) may conveniently be modified to allow evaluation of orally administered test compounds by administering the test compound to conscious cats with indwelling arterial and venous catheters and measuring the effect in preventing an adenosine induced decrease in blood pressure.
• Test compounds which are orally active in this test will show significant adenosine antagonist activity at a dose of 1 - 3 mg/kg or less.
• This test involves the assessment of the effects of a test compound on antagonising the actions of adenosine in lowering heart rate and producing vasodilation (as measured by a fall in hind-limb perfusion pressure).
• Beagles (12 - 18 kg) are anaesthetised with sodium pentobarbitone (50 mg/kg, iv).
• the following blood vessels are catheterised: right jugular vein (for infusion of the anaesthetic at approximately 112 mg per hour as a 3 mg/ml solution in isotonic saline), right brachial vein (for administration of drugs and test agents), right brachial artery (for measurement of systemic blood pressure and pulse rate) and the left carotid artery (for administration of adenosine into the left ventricle).
• right jugular vein for infusion of the anaesthetic at approximately 112 mg per hour as a 3 mg/ml solution in isotonic saline
• right brachial vein for administration of drugs and test agents
• right brachial artery for measurement of systemic blood pressure and pulse rate
• the left carotid artery for administration of adenosine into the left ventricle.
• a bolus injection of 1250 U heparin is administered before perfusing the right hindlimb at constant blood flow with blood from the iliac artery.
• the right leg is tied just below the ankle.
• Xamoterol (1 mg/kg) is then administered to the animal to stabilise heart rate at a high level and nitrobenzylthioinosine (NBTI, 0.5 mg/kg) to inhibit the uptake of adenosine.
• NBTI nitrobenzylthioinosine
• the animal is sensitised to adenosine during the equilibration time following NBTI by carrying out a dose response curve (DRC). During this time any blood gas or pH imbalance is corrected.
• a control DRC is performed followed by up to three DRC's after cumulative administration of the test compound (as described in (d) above). Each DRC is carried out 15 minutes after administration of test compound and after the measured parameters of heart rate and hindlimb perfusion pressure have returned to a stable state. Similarly,
• the amount of adenosine required to cause a 50% fall in measured parameter (ED 50 ) i.e. heart rate and hindlimb perfusion pressure is calculated for each does of test compound and a Schild plot constructed. From this plot a K B value is determined for antagonism of heart rate response and vasodilator response to adenosine. Test compounds which are active in this test will possess a K B value of 1 mg/kg (or much less) for vasodilator response to adenosine.
• This test involves assessment of the effect of a test compound to antagonise the vasodilatation response which occurs during twitch contraction of skeletal muscle.
• the vasodilation is mediated partly by the release of endogenous adenosine from the contracting skeletal muscle.
• Cats (2.4-3.6 kg) are anaesthetised with sodium pentobarbitone (50 mg.kg- 1 ip).
• the following blood vessels are catheterized: left jugular vein (for infusion of anaesthetic, at approximately 0.12 mg- 1 min- 1 as a 6 mg.mi- 1 solution in isotonic saline), right external jugular vein (for administration of drugs and test compounds), right common carotid artery (for measurement of systemic arterial blood pressure and pulse rate) and right brachial artery (for withdrawal of blood).
• Blood flow to the left hind limb is measured with an electromagnetic flow probe around the left external iliac artery.
• the whole of the left hind limb is made to contract at 3Hz for 20 minutes duration by stimulating the sciatic and femoral nerves.
• Active tension produced by the extensor digitorum longus and peroneous longus muscles is measured isometrically with a force transducer.
• Exercise is repeated twice within the same animal, in either the absence or presence of the test compound.
• Test compounds are assessed for their ability to reduce the vasodilatation during skeletal muscle contraction. Test compounds which are active in this test will show significant inhibition of vasodilation during exercise at a dose of 1 mg/kg (or much less).
• the compounds of the invention are generally best administered to warm-blooded animals for therapeutic or prophylactic purposes in the treatment or prevention of cardiovascular diseases and adverse conditions in the form of a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, in a mixture or together with a pharmaceutically acceptable diluent or carrier.
• Such compositions are provided as a further feature of the invention.
• a compound of formula I will be administered orally, intravenously or by some other medically acceptable route (such as by inhalation, insufflation, sub-lingual or transdermal means) so that a dose in the general range, for example, 0.001 mg to 10 (and more particularly in the range, for example, 0.05 to 5 mg/kg) mg/kg body weight is received.
• a dose in the general range for example, 0.001 mg to 10 (and more particularly in the range, for example, 0.05 to 5 mg/kg) mg/kg body weight is received.
• the precise dose administered will necessarily vary according to the nature and severity of the disease or condition being treated and on the age and sex of the patient.
• a composition according to the invention may be in a variety of dosage forms.
• it may be in the form of tablets, capsules, solutions or suspensions for oral administration; in the form of a suppository for rectal administration; in the form of a sterile solution or suspension for administration by intravenous or intramuscular injection; in the form of an aerosol or a nebuliser solution or suspension, for administration by inhalation; in the form of a powder, together with pharmaceutically acceptable inert solid diluents such as lactose, for administration by insufflation; or in the form of a skin patch for transdermal administration.
• the compositions may conveniently be in unit dose from containing, for example, 5 - 200 mg of the compound of formula I or an equivalent amount of a pharmaceutically acceptable salt thereof.
• compositions may be obtained by conventional procedures using pharmaceutically acceptable diluents and carriers well known in the art.
• Tablets and capsules for oral administration may conveniently be formed with an enteric coating (such as one based on cellulose acetate phthalate) to minimise the contact of the active ingredient of formula I with stomach acids.
• compositions of the invention may also contain one or more agents known to be of value in the diseases or conditions of the cardiovasculature intended to be treated.
• agents known to be of value in the diseases or conditions of the cardiovasculature intended to be treated may contain, in addition to the compound of formula I, for example: a known platelet aggregation inhibitor, prostanoid constrictor antagonist orsynthase inhibitor(thromboxaneA 2 antagonistorsynthase inhibitor), cyclooxygenase inhibitor, hypolipidem- ic agent, anti-hypertensive agent, inotropic agent, beta-adrenergic blocker, thrombolytic agent or a vasodilator.
• a known platelet aggregation inhibitor for example: a known platelet aggregation inhibitor, prostanoid constrictor antagonist orsynthase inhibitor(thromboxaneA 2 antagonistorsynthase inhibitor), cyclooxygenase inhibitor, hypolipidem
• the compounds of formula I are also useful as pharmacological tools in the development and standardisation of test systems for the evaluation of new cardiovascular agents in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice.
• the required starting material was prepared as follows:-1) [(2-furanylcarbonyl)amino]propanedioic acid, diethyl ester (123g, 457mM) was added to a stirred mixture of 2-methyl-2-thio-pseudourea sulphate (63.8g, 229mM) and sodium methoxide (25% w/w) (105ml), in methanol (500ml).
• the mixture was stirred at ambient temperature for 15hrs, then heated under reflux for 24 hours. Fur- thersodium methoxide solution (260ml) was added and the mixture refluxed for further24 hours, cooled, poured into water and acidified with concentrated hydrochloric acid to PH ⁇ 3. The mixture was then cooled to 0°C for 4 hours and the resultant precipitate separated by filtration. The solid was washed with methylene chloride, then acetone, and air-dried. Further purification was achieved by suspension in hot water for 0.5 hours. The solid was filtered off and dried at 70°C for 15 hours in a vacuum oven.
• the starting material was prepared as follows:-
• the starting material was prepared as follows:-
• 6-Amino-8-(2-furyl)-2-methylthio-1 H-purine m.p. >250°C; NMR; DMSO-d 6 ; 2.4-2.5 (s, 3H, SCH3), 2.8-3.8 (br, 1H, NH), 6.7(d, 1H, furan-H), 7.1 (d, 1H, furan-H), 7.1-7.25 (s, 2H, NH 2 ), 7.8-7.9(d, 1H, furan-H).
• Example 10 The starting materials for Examples 10, 11, 12 were prepared as described in Example 5 starting from 4,6-diamino-2-met hylthio-5-nitrosopyrimidine.
• the starting material was prepared as follows:-
• the starting material was prepared as follows:-
• the above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
• the tablets may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Pain & Pain Management (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=10705181

Family Applications (1)

Country Status (5)

Cited By (33)

Families Citing this family (3)

Family Cites Families (9)

• 1991
  • 1991-11-25 GB GB919125001A patent/GB9125001D0/en active Pending
• 1992
  • 1992-11-06 CA CA002082333A patent/CA2082333A1/en not_active Abandoned
  • 1992-11-19 EP EP19920310544 patent/EP0544445A3/en not_active Withdrawn
  • 1992-11-20 US US07/979,019 patent/US5300509A/en not_active Expired - Lifetime
  • 1992-11-25 JP JP4315388A patent/JPH06157540A/ja active Pending
• 1994
  • 1994-01-13 US US08/181,202 patent/US5500428A/en not_active Expired - Lifetime

Also Published As

Similar Documents

Legal Events